Yuliang Xiang

Yuliang Xiang

Auto-generated profile, based on publicly available information

Yuliang Xiang

School of Public Health, Fudan University, Shanghai, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2023 in International Journal of Technology Assessment in Health Care
Verified
Journal Article
Closed access
PDF file
YXYuliang Xiang
Yuliang Xiang
LGLei Gan
Lei Gan
HDHeyue Du
Heyue Du
QHQiukui Hao
Qiukui Hao
BABert Aertgeerts
Bert Aertgeerts
MHMing Hu
Ming Hu
Objectives: The latest international guideline recommended the add-on therapy of ezetimibe and PCSK9 inhibitors in selected people for the secondary prevention of cardiovascular diseases (CVDs). However, it remains unclear whether these regimens fit the Chinese healthcare system economically. Methods: Based on the Chinese context, this simulation study evaluated four therapeutic strategies including the high-dose statin-only group, ezetimibe plus statin group, PCSK9 inhibitors plus statin group, and PCSK9 inhibitors plus ezetimibe plus statin group. The team developed a Markov model to estimate the incremental cost-effectiveness ratio (ICER). With each 1-yr cycle, the simulation subjects could have nonfatal cardiovascular events (stroke and/or myocardial infarction) or death (vascular or nonvascular death event) with a follow-up duration of 20 yr. Cardiovascular risk reduction was gathered from a network meta-analysis, and cost and utility data were gathered from hospital databases and published research. Results: For Chinese adults receiving high-dose statins for secondary prevention of CVDs, the ICER was US$68,910 per quality-adjusted life year (QALY) for adding PCSK9 inhibitors, US$20,242 per QALY for adding ezetimibe, US$51,552 per QALY for adding both drugs. Given a threshold of US$37,655 (three times of Chinese GDP), the probability of cost-effectiveness is 2.9 percent for adding PCSK9 inhibitors, 53.1 percent for adding ezetimibe, and 16.8 percent for adding both drugs. To meet the cost-effectiveness, an acquisition price reduction of PCSK9 inhibitors of 33.6 percent is necessary. Conclusion: In Chinese adults receiving high-dose statins for the secondary prevention of CVDs, adding ezetimibe is cost-effective compared to adding PCSK9 inhibitors and adding both drugs.

24 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
YXYuliang Xiang
Yuliang Xiang
YXYue Xu
Yue Xu
YYYi Yang
Yi Yang
JWJunling Weng
Junling Weng
YWYan Wei
Yan Wei
YCYingyao Chen
Yingyao Chen
Background: Secondary prevention after ischaemic stroke depends on uninterrupted medication, yet how post-discharge care unfolds, and which survivors fall away, remains poorly characterised in the Western Pacific region. We aimed to identify care trajectories after minor ischaemic stroke and their associations with recurrence and death. Methods: In a retrospective cohort using the citywide basic medical insurance claims database of S, eastern China (20·04 million insured; 2021–2024), we included all first-ever ischaemic stroke hospitalisations. Within pre-specified severity categories, we characterised 12-month care by multichannel sequence analysis of care setting and secondary-prevention medication, with a claims-based death proxy. In the minor-stroke group (primary focus), we examined determinants of membership and, with a 12-month landmark, associations with recurrent ischaemic stroke (primary outcome) and presumed death by competing-risk models. Findings: Of 60 344 patients, 38 287 (63·4%) had minor stroke. Three trajectories emerged: sustained care with secondary prevention (68·4%); a secondary-prevention gap (26·8%), still attending care (92% of quarters) but largely without preventive medication; and presumed death or permanent exit (4·8%). Versus sustained care, the gap group had higher recurrent stroke (24-month incidence 33·9% vs 29·1%; cause-specific hazard ratio 1·13, 95% CI 1·06–1·21) and presumed death (hazard ratio 1·57, 95% CI 1·33–1·84). Gap membership was more common after a non-tertiary first admission (secondary vs tertiary hospital, relative risk ratio 1·71, 95% CI 1·60–1·82) and among women. Interpretation: A quarter of minor-stroke survivors remained in contact with care yet disengaged from secondary prevention, a claims-identifiable, modifiable equity target in the Western Pacific and comparable tiered health systems.

8 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
YXYuliang Xiang
Yuliang Xiang
YXYue Xu
Yue Xu
YCYingyao Chen
Yingyao Chen
Background: Many ageing societies rely on grandparents for childcare, but evidence on grandchild care and grandparents' health is mostly from single countries and inconsistent. We aimed to estimate within-person associations of grandchild care with cognitive, mental, and physical health across countries.Methods: In this longitudinal study, we used harmonised 2000–20 data from six ageing cohorts in 25 countries in Asia, Europe, and the Americas, including adults aged 50 years and older with grandchildren. Outcomes were memory, depressive symptoms, mobility limitations, life satisfaction, and self-rated health. Individual fixed-effects models compared periods with and without grandchild care within the same person; country-specific estimates were pooled by random-effects meta-analysis, and meta-regressions examined country-level modifiers.Findings: Of 168 203 adults (95 867 [57·0%] women; 480 232 observations), 40 877 (24·3%) started or stopped providing care. Memory scores were 0·034 SD higher during care (95% CI 0·027–0·040), equivalent to 0·7–1·2 years of age-related decline, with positive estimates in 24 of 25 countries (I²=0%). Pooled associations were close to zero for depressive symptoms (−0·007 SD, −0·025 to 0·010; I²=65%) and mobility limitations (0·002 SD, −0·012 to 0·017; I²=61%), but mobility limitations during care were greater in countries with larger households (slope 0·111, 0·048–0·173) and lower female labour-force participation. Life satisfaction and self-rated health were slightly higher.Interpretation: Grandchild care was consistently associated with slightly better memory; associations with depressive symptoms and mobility limitations depended on national context. Family-care policies should consider grandparents' health, particularly where formal childcare is scarce and households are larger.